Table 1.
Demographics of participants in the study.
| HCs (n=20) | NMOSD (n=26) | |
|---|---|---|
| Female, n (%) | 19 (95.0) | 25 (96.3) |
| Age at baseline, median (IQR) | 43.0 (39.3-51.8) | 49.5 (36.5-58.0) |
| Age at onset, median (IQR) | — | 45.5 (34.0-57.3) |
| Disease duration(y), median (IQR) | — | 2.59 (0.63-4.10) |
| ARR at baseline, median (IQR) | — | 0.28 (0.00-0.64) |
| EDSS score, median (IQR) | — | 2.5 (2.0-3.9) |
| AQP4-ab positive, n (%) | — | 24 (92.3) |
| Preventive medications at baseline, n (%) | ||
| No treatment | — | 6 (23.1) |
| oral corticosteroids | 20 (76.9) |
EDSS, Expanded Disability Status Scale; HC, healthy control; NMOSD, neuromyelitis optica spectrum disorders; IQR, interquartile range; Treatment was defined as use of high-dose intravenous steroids, plasma exchange (PE) or intravenous immunoglobulin (IVIG) at relapse stage; Values indicate median (interquartile range) or number (percent).